Update shared on06 Aug 2025
Fair value Increased 21%IDEXX Laboratories’ consensus price target has been sharply raised, reflecting strengthened revenue growth forecasts and a higher future P/E multiple, with fair value increasing from $542.55 to $657.55.
What's in the News
- IDEXX Laboratories raised 2025 earnings guidance, increasing revenue outlook to $4,205–$4,280 million (up $90 million at midpoint) and EPS to $12.40–$12.76 (up $0.40 at midpoint), reflecting strong recurring diagnostics revenue, higher inVue Dx instrument placements, and favorable foreign exchange.
- The company launched the Catalyst Cortisol Test, expanding its Catalyst platform offerings to support diagnosis and management of Addison’s disease and Cushing’s syndrome in dogs, with broad US, Canadian, and upcoming global rollout.
- IDEXX was dropped from the Russell 1000 Dynamic Index.
- Amended bylaws and certificate of incorporation removed all supermajority vote requirements, provided officer exculpation, eliminated Series A Preferred Stock, and elected three Class III directors, with all changes approved by shareholders.
Valuation Changes
Summary of Valuation Changes for IDEXX Laboratories
- The Consensus Analyst Price Target has significantly risen from $542.55 to $657.55.
- The Future P/E for IDEXX Laboratories has significantly risen from 40.16x to 45.42x.
- The Consensus Revenue Growth forecasts for IDEXX Laboratories has risen from 7.9% per annum to 8.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.